Skip to content

Clinical Study on the Efficacy and Safety of Gukang Capsules in the Treatment of Knee Osteoarthritis (Liver and Kidney Deficiency Type)

Clinical Study on the Efficacy and Safety of Gukang Capsules in the Treatment of Knee Osteoarthritis (Liver and Kidney Deficiency Type)

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001496
Enrollment
Unknown
Registered
2026-06-17
Start date
2026-06-30
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis (type with liver and kidney deficiency)

Interventions

Sponsors

Wangjing Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 100 Years

Inclusion criteria

Inclusion criteria: Participants must be aged =50 years, with no gender restriction [16]; meet the Western medical diagnostic criteria for knee osteoarthritis [16]; have unilateral knee involvement, or a contralateral knee joint score (WOMAC) not exceeding that of the target side, with no pharmacological treatment required for the contralateral knee during the study; satisfy the Traditional Chinese Medicine syndrome differentiation criteria for liver-kidney deficiency pattern [17]; at screening, the VAS score for pain during walking on flat ground in the target knee should be =7, and the pain subscale score on the Western University of Ontario and McMaster University Osteoarthritis Index (WOMAC) scale should be =5 [18]; participants must understand and comply with the study protocol, provide informed and voluntary consent, and sign an informed consent form.

Exclusion criteria

Exclusion criteria: Other conditions that may confound the assessment of target knee joint function and pain include: systemic diseases potentially affecting joints (e.g., gouty arthritis, rheumatoid arthritis), chronic inflammatory or connective tissue diseases, neurological disorders, Paget's disease involving the knee, localized pain caused by nerve root syndrome-related lumbar compression, or any other conditions that could interfere with efficacy evaluation; use of corticosteroids within one month prior to screening; administration of nonsteroidal anti-inflammatory drugs, benzothiazines, glucosamine, chondroitin sulfate, or other knee osteoarthritis treatments-including traditional Chinese medicines-within three weeks before screening [16]; intra-articular treatments (including intra-articular injections, joint lavage, or simple arthroscopy) performed or planned during the trial within three months prior to screening; arthroscopic surgery, joint replacement, or other open knee procedures (excluding simple arthroscopy) performed on the non-target knee within six months before screening, or on the target knee previously; severe cardiovascular or cerebrovascular diseases, chronic liver disease (ALT/AST =1.5× upper limit of normal reference range), or renal disease (serum creatinine> upper limit of normal reference range) [19]; known immunodeficiencies (e.g., uncured or active malignancies, organ/bone marrow transplantation, or recent use of immunosuppressants within three months) [19]; pregnancy, suspected pregnancy, planned pregnancy (within three months after study completion), or lactation [19]; individuals with allergic predisposition or known hypersensitivity to trial medications [19]; and patients who participated in other clinical studies within three months prior to screening. Patients with comorbid mental disorders or cognitive impairments who were unable to cooperate with the investigators [19]; patients deemed by investigators as intolerant to the study drug, or those with any other contraindications to participation in this study.

Design outcomes

Primary

MeasureTime frame
Total Score of WOMAC Scale;Changes from baseline in pain, stiffness and physical function subscale scores;

Secondary

MeasureTime frame
Changes from baseline in total WOMAC scale score after 2 weeks of treatment;Changes from baseline in WOMAC pain, stiffness and physical function subscale scores after 2 weeks of treatment;Onset time of pain relief;Time to pain resolution;Proportions of pain onset and pain resolution at 2 and 4 weeks of treatment;Changes from baseline in pain VAS scores at 2 and 4 weeks of treatment;Area under the curve (AUC) of knee pain VAS scores during the trial;Changes from baseline in individual item scores and total score of TCM syndrome after 2 and 4 weeks of treatment;

Countries

China

Contacts

Public ContactHongmei Zhang

Wangjing Hospital, China Academy of Chinese Medical Sciences

wangjingzhm@sina.com13910626823

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 29, 2026